| Q33720707 | "Killing Two Birds with One Stone": Alcohol Use Reduction Interventions with Potential Efficacy in Enhancing Self-Control |
| Q54998102 | A Combination of Naltrexone + Varenicline Retards the Expression of a Genetic Predisposition Toward High Alcohol Drinking. |
| Q30275691 | A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence |
| Q27312608 | A key role for the N/OFQ-NOP receptor system in modulating nicotine taking in a model of nicotine and alcohol co-administration |
| Q34785056 | A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers |
| Q38940577 | Addiction, cognitive decline and therapy: seeking ways to escape a vicious cycle. |
| Q47182010 | Advances in Pharmacotherapy Development: Human Clinical Studies |
| Q90450428 | Advances in the science and treatment of alcohol use disorder |
| Q92312184 | Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder |
| Q48081263 | Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry |
| Q38581812 | Alcohol use disorders. |
| Q49236388 | Alcohol-Induced Increases in Inflammatory Cytokines Are Attenuated by Nicotine in Region-Selective Manner in Male Rats |
| Q89314072 | Alterations in resting-state functional connectivity in substance use disorders and treatment implications |
| Q36103548 | An exploratory evaluation of Take Control: A novel computer-delivered behavioral platform for placebo-controlled pharmacotherapy trials for alcohol use disorder |
| Q104460866 | An integrated behavioural intervention combined with varenicline for heavy-drinking smokers: a randomized pilot study |
| Q38839642 | An overview of alcohol and tobacco/nicotine interactions in the human laboratory |
| Q64983524 | Association of Syndemic Unhealthy Alcohol Use, Cigarette Use, and Depression With All-Cause Mortality Among Adults Living With and Without HIV Infection: Veterans Aging Cohort Study. |
| Q61822090 | Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use |
| Q30841324 | Automatic avoidance tendencies for alcohol cues predict drinking after detoxification treatment in alcohol dependence |
| Q92189687 | Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future |
| Q38594528 | Clinical neuroscience of addiction: similarities and differences between alcohol and other drugs |
| Q48148853 | Co-Administration of Low-Dose Naltrexone and Bupropion Reduces Alcohol Drinking in Alcohol-Preferring (P) Rats. |
| Q34351761 | Cognitive control in alcohol use disorder: deficits and clinical relevance |
| Q38185313 | Combined pharmacotherapies for the management of alcoholism: rationale and evidence to date |
| Q36372867 | Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse |
| Q36877440 | Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokers |
| Q38181213 | Current pharmacological treatment approaches for alcohol dependence |
| Q90597805 | Developing neuroscience-based treatments for alcohol addiction: A matter of choice? |
| Q90308784 | Differential patterns of alcohol and nicotine intake: Combined alcohol and nicotine binge consumption behaviors in mice |
| Q37059221 | Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development |
| Q33929790 | Drug effects on multiple and concurrent schedules of ethanol- and food-maintained behaviour: context-dependent selectivity |
| Q36936258 | Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders |
| Q47275723 | Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial |
| Q37059266 | Effect of Varenicline Combined with High-Dose Alcohol on Craving, Subjective Intoxication, Perceptual Motor Response, and Executive Cognitive Function in Adults with Alcohol Use Disorders: Preliminary Findings |
| Q48180557 | Effects of Long-Term Alcohol Drinking on the Dopamine D2 Receptor: Gene Expression and Heteroreceptor Complexes in the Striatum in Rats |
| Q50042559 | Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users: A Preliminary Laboratory Study |
| Q36363819 | Effects of Varenicline on Neural Correlates of Alcohol Salience in Heavy Drinkers |
| Q49892752 | Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats |
| Q38732866 | Effects of varenicline on alcohol cue reactivity in heavy drinkers |
| Q38870727 | Effects of varenicline on alcohol self-administration and craving in drinkers with depressive symptoms |
| Q48124586 | Effects of varenicline on cognitive performance in heavy drinkers: Dose-response effects and associations with drinking outcomes |
| Q34940888 | Effects of varenicline on ethanol-induced conditioned place preference, locomotor stimulation, and sensitization |
| Q36319552 | Effects of varenicline on operant self-administration of alcohol and/or nicotine in a rat model of co-abuse |
| Q38689594 | Emerging pharmacotherapies for alcohol use disorder |
| Q92326041 | Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials |
| Q43195621 | Evaluation of guanfacine as a potential medication for alcohol use disorder in long-term drinking rats: behavioral and electrophysiological findings. |
| Q38636469 | Feeding Two Birds with One Scone: The Case of Varenicline |
| Q52316006 | From gene networks to drugs: systems pharmacology approaches for AUD. |
| Q58591817 | Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial assessing Efficacy and Safety |
| Q34970821 | Ghrelin receptor (GHS-R1A) antagonism suppresses both alcohol consumption and the alcohol deprivation effect in rats following long-term voluntary alcohol consumption |
| Q36231851 | Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision |
| Q99608705 | Interaction of Heavy Drinking Patterns and Depression Severity Predicts Efficacy of Quetiapine Fumarate XR in Lowering Alcohol Intake in Alcohol Use Disorder Patients |
| Q42623009 | Intermittent Access to Ethanol Induces Escalated Alcohol Consumption in Primates |
| Q47732515 | Letter to Editor in Response to Johnson's Commentary (2017) on the Witkiewitz and Colleagues (2017) Article |
| Q62729760 | Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking |
| Q37060159 | Management of Alcohol Use Disorder in Patients Requiring Liver Transplant |
| Q30399710 | Mechanisms underlying sleep-wake disturbances in alcoholism: focus on the cholinergic pedunculopontine tegmentum |
| Q38718932 | Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models |
| Q47942161 | Medications for alcohol use disorders: An overview |
| Q30871554 | Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials |
| Q34048818 | MiR-153 targets the nuclear factor-1 family and protects against teratogenic effects of ethanol exposure in fetal neural stem cells. |
| Q58131549 | Missed opportunities to test the neuropsychiatric safety--and efficacy--of varenicline among smokers with substance use disorders |
| Q35911952 | Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence: An Exploratory Analysis |
| Q24185773 | Nicotine receptor partial agonists for smoking cessation |
| Q50065382 | Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence |
| Q35960331 | Nicotinic Mechanisms Modulate Ethanol Withdrawal and Modify Time Course and Symptoms Severity of Simultaneous Withdrawal from Alcohol and Nicotine |
| Q28087047 | Nicotinic receptor modulation to treat alcohol and drug dependence |
| Q39136644 | Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors |
| Q89402756 | Overcoming the "Valley of Death" in Medications Development for Alcohol Use Disorder |
| Q36294656 | Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers |
| Q37708082 | Pharmacological approaches to reducing craving in patients with alcohol use disorders |
| Q36684437 | Pharmacotherapy for alcohol use disorder: current and emerging therapies |
| Q36927085 | Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders |
| Q43061723 | Pharmacotherapy of alcoholism - an update on approved and off-label medications |
| Q50317988 | Practical outpatient pharmacotherapy for alcohol use disorder |
| Q37059156 | Preclinical Medication Development: New Targets and New Drugs |
| Q92501996 | Promoting activity of (α4)3(β2)2 nicotinic cholinergic receptors reduces ethanol consumption |
| Q36440595 | Recruitment techniques for alcohol pharmacotherapy clinical trials: A cost-benefit analysis |
| Q47616924 | Reduced Drinking in Alcohol Dependence Treatment, What Is the Evidence? |
| Q41528453 | Relative potency of varenicline or fluvoxamine to reduce responding for ethanol versus food depends on the presence or absence of concurrently earned food |
| Q28083649 | Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis |
| Q41477480 | Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme |
| Q58100058 | State-of-the-art behavioral and pharmacological treatments for alcohol use disorder |
| Q34096925 | Substance abuse among older adults |
| Q34247817 | Substance use in older HIV-infected patients |
| Q99581955 | Suicide Attempt in a 38-Year-Old Patient on Varenicline While Intoxicated With Alcohol |
| Q48305886 | The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target? |
| Q47442429 | The Effect of Varenicline on the Neural Processing of Fearful Faces and the Subjective Effects of Alcohol in Heavy Drinkers. |
| Q48248956 | The Effects of Long-Term Varenicline Administration on Ethanol and Sucrose Seeking and Self-Administration in Male P Rats |
| Q48143336 | The Glycine Receptor-A Functionally Important Primary Brain Target of Ethanol. |
| Q41392387 | The monoamine stabilizer (-)-OSU6162 counteracts downregulated dopamine output in the nucleus accumbens of long-term drinking Wistar rats |
| Q47550611 | The nicotinic receptor drug sazetidine-A reduces alcohol consumption in mice without affecting concurrent nicotine consumption |
| Q35788371 | The role of varenicline on alcohol-primed self-administration and seeking behavior in rats |
| Q91649780 | Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking |
| Q26799819 | Translating Alcohol Research: Opportunities and Challenges |
| Q48004085 | Varenicline Reduces Alcohol Intake During Repeated Cycles of Alcohol Reaccess Following Deprivation in Alcohol-Preferring (P) Rats. |
| Q39196596 | Varenicline Reduces Context-Induced Relapse to Alcohol-Seeking through Actions in the Nucleus Accumbens |
| Q33929766 | Varenicline decreases ethanol intake and increases dopamine release via neuronal nicotinic acetylcholine receptors in the nucleus accumbens |
| Q43188062 | Varenicline decreases nicotine but not alcohol self-administration in genetically selected Marchigian Sardinian alcohol-preferring (msP) rats. |
| Q34097966 | Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals |
| Q50088319 | Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: A randomized controlled trial |
| Q40491939 | Varenicline for treatment of alcohol dependence: a randomized, placebo-controlled trial |
| Q35219810 | Varenicline in the treatment of alcohol use disorders |
| Q88959955 | Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial |
| Q47373861 | Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms |